Divi's Labs Q2 FY27: Revenue Surges 32% to ₹3,770 Crore, PAT Jumps 64%
Divi's Laboratories reported Q2 FY27 consolidated revenue of ₹3,770 crore, a 32% YoY increase. PAT grew 64% to ₹1,127 crore. For H1 FY27, revenue was ₹6,907 crore and PAT was ₹2,029 crore. Custom synthesis accounted for 62% of H1 sales, with generics at 38%. Capital expenditure for H1 stood at ₹1,223 crore.
The substantial increase in revenue and profit, along with positive commentary on business segments and capital investments, indicates a significant positive impact on the company's financial standing and future prospects.
The company reported significant year-on-year growth in both revenue and profit for the quarter and half-year, indicating strong financial performance.
Divi's Laboratories Limited announced its financial results for the second quarter and half year ended September 30, 2026. The company reported a consolidated total income of ₹3,770 crore for Q2 FY27, a 32% increase year-on-year from ₹2,860 crore in the corresponding quarter of the previous fiscal year. Profit before tax grew by 65% to ₹1,505 crore from ₹912 crore, while profit after tax rose by approximately 64% to ₹1,127 crore from ₹689 crore.
For the first half of FY27, consolidated total income reached ₹6,907 crore, up from ₹5,389 crore in the same period last year. Profit before tax for the half-year increased to ₹2,685 crore from ₹1,645 crore, and profit after tax grew to ₹2,029 crore from ₹1,234 crore, marking a 64% increase.
Exports accounted for approximately 90% of standalone sales revenue, with Europe and North America contributing about 75%. Standalone revenue saw a 17% year-on-year growth on a constant currency basis for the first half. Generics contributed 38% to sales revenue, while custom synthesis accounted for 62% in the first half.
The nutraceutical business recorded ₹571 crore in revenue for the first half. Net material consumption was 32% of sales revenue, down from 40% last year. The company reported a net forex gain of ₹20 crore in the first half, compared to ₹103 crore last year. Capitalization for the second quarter was ₹772 crore, bringing the first-half total to ₹1,223 crore. Capital work in progress stood at ₹1,638 crore as of September 30, 2026.
The company held cash balances of ₹2,181 crore, with trade receivables at ₹3,705 crore and inventories at ₹5,325 crore. Management highlighted stable performance in the Generic business with healthy volume growth, while the Nutraceutical segment is expanding capabilities. Custom Synthesis customer engagement remains strong with several programs advancing. Major capital investment programs are progressing through validation stages. The peptide portfolio is growing, with capacity expansions underway. Technology development, including flow chemistry and biocatalysis, is integral to the manufacturing strategy. Unit 3 continues to play a significant role in the production network, supporting backward integration.
What to do with a filing like this
Divi's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Divi's Laboratories Limited. Read the original for the full detail.